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Abstract 
 In 1960, Dr. Paul Janssen of the Janssen Company synthesized fentanyl. It is a 
rapid-acting analgesic that, unlike similar analgesics around that time, did not have 
negative cardiovascular effects. Fentanyl, and its derivatives, are strong μ-opioid receptor 
agonists. Rates of fatal opioid overdoses involving fentanyl have increases rapidly over 
the past two decades Due to these increasing concerns related to fentanyl and its 
derivatives, it is important to not only study fentanyl and its known derivatives, but to 
also study and understand potential new derivatives and how all these compounds interact 
with the opioid receptors. 
This study examined the interactions that take place between fentanyl, and its 
analogs, and the opioid receptors they interact with in the body. The molecular modeling 
software, Maestro, was used in order to study these specific interactions. Fentanyl and its 
analogs were sketched and prepped for docking to the receptors using Maestro. The 
opioid receptor chosen for this study from came from an available, active-state crystal 
structure. The data from this study identified specific interactions that take place between 
these drugs and the binding site of corresponding opioid receptor. 
The designed derivatives used in this study were derivatives of the following 
analogs: N-methyl fentanyl, fentanyl, carfentanyl, lofentanyl, remifentanil, sufentanil, 
and alfentanil. Based on the resulting ligand interaction diagrams, it was determined that 
many of the fentanyl ligands follow expected binding patterns within the binding pocket. 
Key residue interactions included aromatic stacking interactions, hydrophobic 
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interactions, polar interactions and hydrogen bonding. These interactions corresponded to 
varying structural changes between fentanyl and its analogs. The interactions and 
structural changes were used to help better understand the potency and toxicity of 
fentanyl and fentanyl analogs. Future work will include using the results of this study to 
help predict potential new analogs of fentanyl before they appear on the drug market. 
Scientists and law enforcement will have advanced knowledge on various fentanyl-
related substances to improve both detection and treatment of fatal overdose cases. 
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Introduction 
In 1960, Dr. Paul Janssen of the Janssen Company synthesized fentanyl, a strong 
µ-opioid receptor agonist. It is a rapid-acting analgesic that, unlike similar analgesics 
around that time, did not have negative cardiovascular effects.1  It was not until 1972 that 
fentanyl overdoses began to be reported, as increasing amounts and additional methods of 
administration became available.1 From 1999 to 2011, the number of fatal opioid 
analgesic overdoses quadrupled and, for the year 2015, the death toll in the US totaled 
33,091.2  The main cause for this spike in overdose deaths are the result of drug dealers 
lacing heroin with fentanyl in order to increase the user’s high. In addition to the US 
regulations on fentanyl and various fentanyl derivatives, other countries are attempting to 
stem the tide of this epidemic as well. The increasing issue has been that  as soon as a 
country has regulated a specific  derivative of fentanyl, another similar compound is 
found on the market, causing fentanyl overdose deaths to likely be very underreported.2 
Due to these increasing concerns related to fentanyl and its derivatives, it is important to 
not only study fentanyl and its known derivatives, but to also study and understand 
potential new derivatives and how all these compounds interact with the opioid receptors.  
 
Figure 1. Fentanyl structure. 
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Figure 3. This figure shows every derivative designed from the seven principle 
structures.  
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There have been various studies on fentanyl and its derivatives using molecular 
docking to better understand the binding of these drugs to the opioid receptors.  A study 
was conducted in 2000 by the Department of Medicinal Chemistry at the University of 
Minnesota where four scientists investigated the ligand binding modes of fentanyl and 
several of its derivatives.3 The docking in this study was done using the DOCK 3.5 
program package. This study looked at specific structural groups of the fentanyl 
derivatives and how they would bind to the receptor. These structural groups included 
groups like the N-phenethyl and N-phenylpropanoid group. The authors were able to 
determine, through molecular docking, where the structural groups would bind 
specifically in the receptor. 3A study in 2005 found that substitution on the piperidine 
ring on fentanyl affects both the binding and the activity of the ligand at the µ-opioid 
receptor. This study investigated the binding of p-fluorofentanyl and carfentanyl, two of 
the most potent fentanyl derivatives.4 Important amino acids were identified as important 
for both ligand binding and receptor activation. These amino acids include Ile 322, Gly 
325, Val 300, Met 203, Leu 200, Val 143, and Ile 144.4 The Mossakowski Medical 
Research Centre Polish Academy of Sciences conducted a study in 2016 that discussed 
some interesting developments in ligand binding and receptor activity of some of these 
same fentanyl derivatives. While many fentanyl derivatives are highly µ-selective, not all 
are including lofentanyl. This study determined that even though lofentanyl isn’t highly 
µ-selective, it has the highest µ-affinity of all the analogs studied. However, carfentanyl 
was found to be both a high-affinity analog and the most µ-selective.5  
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In 2018, a study was released by the US FDA’s Center for Drug Evaluation and 
Research (CDER) using molecular docking to predict binding affinities of 
pharmacologically unclassified designer substances.5 The purpose of this study was to 
determine binding affinities of unclassified fentanyl analogs to help in the emergency, 
temporary scheduling of these substances. The molecular docking software used in this 
study was Triangle Matcher. The authors of this study were able to predict binding 
affinity ranges for the derivatives using the virtual screening process of molecular 
docking, as seen in Table 1.   
Table 1. This table shows various Ki values for the ligands that were docked during the 
US FDA’s binding studies research.3  
 
For this research, fentanyl and an assortment of fentanyl derivatives were docked 
into µ-opioid receptor via the molecular docking software Maestro. The µ-opioid receptor 
used in this study was downloaded from the Protein Data Bank, PDB file “5C1M”. The 
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crystal structure of this µ-opioid receptor was developed by Huang et al. in 2015.5 This 
µ-opioid receptor structure is bound to the morphinan agonist BU72.5 A variety of 
information will be gathered using the Maestro software and among the data to be 
acquired will be information as to which amino acids residues are involved in the binding 
and where the structures bind to the receptor. Translated, this information will be able to 
inform as to the potency and possible effects of fentanyl and its various derivatives, 
providing law enforcement and other researchers the data necessary to improve the 
detection and identification of possible fentanyl-related illicit drugs. 
Fentanyl related deaths are increasing by the day and more fentanyl derivatives, 
some more potent than its predecessors, are being found laced in heroin and cocaine. 
Some of the newer fentanyl-related substances may not even be detected by modern 
instruments.  As science develops and becomes more adept at drug discovery and 
detection, the fatal effects of fentanyl and its derivatives becomes more pronounced as 
well. It is therefore imperative that scientist stay ahead of the illegal drug trade and part 
of this can be accomplished by using cutting-edge technology to investigate ligand 
binding in regards to illegal substances, sometimes before they even enter the market. 
The purpose of this research is to allow scientists and law enforcement advanced 
knowledge on various fentanyl-related substances to improve both detection and 
treatment of fatal overdose cases. 
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Methods 
The goal of this research was to investigate fentanyl and various fentanyl derivatives to 
compare their effects on the µ-opioid receptor in the human body. This research was 
completed with the molecular modeling software Maestro by Schrödinger.4 
Protein Preparation: 
First, the receptor model was from a published crystal structure, which was 
downloaded as a PDB file, 5C1M, and imported into the Maestro software.5 The structure 
of this receptor can be seen below in Figure 4.  
 
Figure 4. This is the three-dimensional µ-opioid receptor model 5CIM.5 
. 
In order to fix common protein structure issues, an application called Protein 
Preparation Wizard was used to ensure an accurate representation of the receptor model 
being used. The application accounts for missing atoms and residues, as well as side 
chain errors. This protein was prepared to ensure that the known essential residues for 
binding with the µ-opioid receptor were present in the binding pocket. These essential 
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residues include HIS 54, TYR 148, ASP 147 and MET 151.6 The protein prepped for this 
study was prepared by Dr. Pankaj Pandey.  
Ligand Preparation: 
The next step was the preparation of the ligand. The ligands were sketched in 2D 
within the Maestro program. After the structures were drawn, the LigPrep protocol was 
used to change the 2D structure into a 3D structure. The ligands chosen for this research 
include fentanyl, carfentanyl, lofentanyl, sufentanil, and other similar derivatives.  
Grid Generation: 
After the protein and ligand had been properly prepared, a docking receptor grid 
was created around the binding pocket of the receptor model. This was done using the 
grid generation protocol that is a part of the Maestro program. In order to determine 
where the binding pocket is located, the morphinan derivative BU72, which was bound in 
the binding pocket of the crystalline μ-opioid receptor used in the study, was located. 
Since this derivative is bound to the receptor, the location of the compound indicates the 
area of the binding pocket. The grid was therefore formed around BU72, ensuring the 
correct location and space of the binding pocket for further ligand docking. By 
determining a grid around the binding pocket of the receptor, the ligands are able to dock 
more accurately to the receptor, which occurs during the glide docking. 
Glide Docking: 
 After the grid was generated, the ligand was then bound to the receptor model 
using the glide docking protocol. This program docks the ligands that have been created 
and prepared in the earlier steps using the standard precision (SP) method. For each 
ligand, approximately 5 poses were output and the best pose was determined by the most 
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negative docking score, or GlideScore, in combination with the Glide Emodel Score. The 
GlideScore maximizes the separation of compounds with strong binding affinity from 
those that have little to no binding affinity. enclosure. The calculated Glide Emodel score 
places more emphasis on the force field components of the binding. These components 
include van der Waals and electrostatic energies and are important when comparing 
ligands of the same pose. After the glide docking, ligand interaction diagrams were 
produced for every pose of each ligand. The two-dimensional ligand interaction diagrams 
show a view of the binding pocket of the receptor with the ligand bound as well as the 
specific residues that are interacting with the ligand. Each type of ligand - receptor 
interaction in the binding pocket are also illustrated through color-coding of the residues. 
These interactions, hydrogen bonding and π- π stacking for example, are even measurable 
in angstroms using the ligand interaction diagrams. The best pose interaction diagrams of 
each specific ligand were thoroughly analyzed and compared to seek trends in structural 
characteristics and residue interactions. 
Prime MM-GBSA:  
 Following the docking of the ligands to the prepared µ-opioid receptor, binding 
energy estimations were done using the Prime Molecular Mechanics/Generalized Born 
Surface Area (prime MM-GBSA) protocol.  In the Maestro software, this protocol is used 
to estimate the relative binding affinities of the ligands to the receptor. The prime MM-
GBSA values given by Maestro are in kcal/mol. Although these values are not expected 
to be the same as the binding affinities found in the literature, the ranking of the values 
are expected to produce the same ranking as the literature values.7  
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Results & Discussion 
Fentanyl and some fentanyl analogs were drawn and docked to the μ-opioid 
receptor model 5CIM (5). Fentanyl, N-methyl fentanyl, carfentanyl, lofentanyl, 
alfentanil, sufentanil and remifentanil were used to design potential derivatives. The best 
poses for these ligands were selected based on their GlideScore and Emodel values. Each 
docked ligand resulted in a diagram showing the various amino acid interactions 
occurring with the ligand within the binding pocket. Using these interaction diagrams, 
comparisons were drawn between the different ligands. Many of the same residues are 
seen in most of the ligands, including the popular Asp 147, Trp 293, and Tyr 336. The 
presence of these amino acid residues as well as their docking scores is shown in Table 2.  
Each of these amino acids also interact with each appropriate ligand and the type of 
interactions can also been seen in Tables A-1 to A-23 (salt-bridge, hydrogen bonding, π-π 
bonding, and one π-cation bond). These ligand interaction diagrams were analyzed at 5 
angstroms. The top poses for each ligand were also used to calculate their MM-GBSA 
values. Twenty-four fentanyl ligands were investigated in four groups. The designed 
intermediate ligands were assigned descriptive names, depending on the functional group 
or atom added to the structure. The first group of composed of N-methyl fentanyl, N-
ethyl, N-propyl fentanyl, and fentanyl. The second group contained remifentanil and 
remifentanil (carboxylic acid). The third group contained carfentanyl (methyl), 
carfentanyl (ethyl), carfentanyl (aldehyde), carfentanyl (ketone), carfentanyl (carboxylic 
acid), carfentanyl, and lofentanyl. The last group contained alfentanil (N), alfentanil (N2), 
alfentanil (N3), alfentanil (N4), alfentanil (methyl1), alfentanil (DBC), alfentanil (DBO), 
alfentanil (methyl2), alfentanil (ethyl), and sufentanil. 
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N-Methyl to Fentanyl 
The first few structures that were analyzed included N-methyl fentanyl, fentanyl, 
and two derivatives that were designed from these two compounds.  
 
Figure 5. Structures of N-methyl fentanyl, N-ethyl fentanyl, N-propyl fentanyl, 
and fentanyl. 
 
As can be seen below in Table 3, many different residues are seen within the binding 
pocket of N-methyl fentanyl, N-ethyl fentanyl, N-propyl fentanyl and fentanyl. The 
majority of these interactions are with hydrophobic amino acids. Specifically, amino 
acids Val 300, Ala 240, Met 151, Ile 144, Cys 321, and Tyr 326 present in all four 
diagrams. As can also be seen in Table 6, the number of hydrophobic interactions 
increases as the methyl chain grows into fentanyl. Polar amino acids, while in shorter 
supply, show an increase in amount as the methyl chain grows. 
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Table 3. This table shows the number of each type of reside found inside the 
binding pocket.  
 
 
Figure 6. This table compares the number of interactions present within the binding 
pocket for each ligand in Table 3.  
Note the overwhelming dominance of hydrophobic resides within each binding 
pocket (blue-green). The next popular interaction is of polar residues (light blue). 
Positively charged residues (green) are absent from the binding pockets of N-methyl, N-
ethyl, and N-propyl fentanyl. Exactly one negatively charged residue and one glycine 
residue were found in all seven compounds. 
The ligands chosen for Table 3 show the progression of N-methyl fentanyl to 
fentanyl, as well as the progression from remifentanil (carboxylic acid) to remifentanil 
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and heroin for comparison. Based on the ligand diagrams for these compounds, all 
interact with Asp 147 via hydrogen bonding and a salt bridge. N-methyl fentanyl, N-ethyl 
fentanyl and fentanyl all show a π-π stacking interaction with Trp 293. The ligand 
diagram for fentanyl shows that it has an additional π-π bond with Tyr 326. In addition to 
analyzing the interaction diagrams for each of these ligands, the docking scores were also 
compared. These scores can be seen in Table 6. N-methyl fentanyl shows a docking score 
of -5.742 and with the addition of the extra methyl group to N-ethyl fentanyl, the binding 
score increases to -5.476. A similar pattern is seen with the further addition of a methyl 
group to N-propyl fentanyl which shows a binding score of -5.333. The addition of the 
benzene group at the end of the methyl chain to create fentanyl, however, results in a 
much negative binding score of -6.870, a significant decrease. 
Remifentanil (ca) to Remifentanil 
 The next ligands to be analyzed include remifentanil and its derivative, 
remifentanil (ca). These ligands are similar to N-methyl, N-ethyl, and N-propyl fentanyl 
in that the changes to the compound occur on the N-alkyl chain. Remifentanil (ca) ends 
with a carboxylic acid group while remifentanil end with an ester group. The two 
structures of remifentanil can be seen in Figure 7. 
 
Figure 7. The molecular structures of remifentanil and remifentanil (ca). 
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As can be seen in Table 6, the docking score of remifentanil (ca) decreases as the 
carboxylic acid group changes to an ester.  
 In terms of interactions with the surrounding amino acid residues, remifentanil 
(carboxylic acid) shows hydrogen bonding and a salt bridge interaction between the 
nitrogen on the piperidine ring and Asp 147. Remifentanil, however, shows no 
interactions with any of its surrounding residues.  
Carfentanyl (methyl) to Lofentanyl 
 Both carfentanyl and lofentanyl are popular derivatives of fentanyl that are 
commonly seen on the streets. In this next section, the ligand interactions of carfentanyl 
and lofentanyl were compared with the diagrams of possible derivatives. A diagram 
showing the growth of each ligand into the next can be seen in Figure 8.  
 
 
Figure 8. The molecular structures of carfentanyl (methyl) and lofentanyl, including 
every intermediate structure.  
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Similar to the previously mentioned ligands, all the carfentanyl compounds show 
an abundance of hydrophobic interactions within the binding pocket. Carfentanyl and 
carfentanyl (ethyl) have the greatest number of hydrophobic amino acids within the 
binding pocket. Also, in a similar pattern to the previous ligands, polar compounds were 
second most numerous. Both carfentanyl (ketone) and carfentanyl (carboxylic acid) show 
an absence of positively charged residues, while carfentanyl (methyl) and carfentanyl 
(aldehyde) have no glycine residue. Throughout the carfentanyl structures and lofentanyl 
ligand diagrams, many of the same amino acid residues appear. These include Trp 318, 
Ile 144, Val 300 and Met 151. All structures except for carfentanyl (aldehyde) contain 
Cys 140 while carfentanyl (carboxylic acid), carfentanyl, and lofentanyl contain the Ala 
117 residue.  
 
Table 4. This table shows the exact number of each type of amino acid residue 
found within each ligand binding pocket. 
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Figure 9. This table compares the number of interactions present within the 
binding pocket for each ligand in Table 4.  
 
Note the overwhelming dominance of hydrophobic resides within each binding 
pocket (blue-green). The next popular interaction is of polar residues (light blue). 
Positively charged residues (green) are present in each ligand diagram except for those 
from the binding pocket of carfentanyl (k) and carfentanyl (ca). Exactly one negatively 
charged residue and one glycine residue were found in all nine compounds, while one 
glycine is found in all binding pockets except for carfentanyl (methyl) and carfentanyl 
(aldehyde).  
All structures observed in this category show both hydrogen interactions and salt 
bridge interactions between the nitrogen on the piperidine ring and Asp 147. Carfentanyl 
and carfentanyl (ethyl) both show two π-π stacking interaction with the benzene ring on 
the aniline ring, while carfentanyl (aldehyde), carfentanyl (ketone), and carfentanyl 
(carboxylic acid) show only one π-π stacking interaction. All π-π stacking interactions 
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occur with Trp 293 or a combination of Trp 293 and Tyr 326 except for the interaction on 
carfentanyl (aldehyde). It’s single π-π stacking interaction occurs with Hie 297 (a 
histidine with a hydrogen on its epsilon nitrogen) and a π-cation interaction, also with Hie 
297. This is the only ligand observed in this research which displays an interaction like 
this one. 
Alfentanil (N) to Alfentanil (e) & Sufentanil  
 In contrast with carfentanyl and lofentanyl, alfentanil and sufentanil are not seen 
in drug abuse cases and are instead the popular forms of fentanyl used in hospitals for 
anesthesia. Because of the similarity in structure and use, it was necessary to compare 
these two ligands and their possible derivatives next. Figure 10 shows the progression 
between each ligand structure.  
 
Figure 10. The molecular structures of alfentanil (N) to alfentanil (e), including every 
intermediate in between. 
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Note the overwhelming dominance of hydrophobic resides within each binding 
pocket (blue-green). The next popular interaction is of polar residues (light blue). There 
are no positively charged residues (green) present in alfentanil (N2), alfentanil (N4), 
alfentanil (m2) and alfentanil (e). One glycine residue was found in all ten compounds 
except for alfentanil (DBO). 
 
Table 5. This table shows the exact number of each type of amino acid residue 
found within each ligand binding pocket. 
 
 
Figure 11. This table compares the number of interactions present within the binding 
pocket for each ligand in Table 5.  
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Hydrophobic residues again dominated the ligand diagrams, averaging 19 resides 
per diagram. Polar residues were again next common. Each showed a negatively charged 
interaction and all structures but alfentanil (DBO) showed a glycine residue. Positively 
charged residues varied somewhat between the structures. Alfentanil (m1) and alfentanil 
(DBC) both show two positively charged residues within their binding pockets, while all 
other structures either have a single negative residue or none.  
 Unlike many of the ligands observed previously in this research, many alfentanil 
structures showed different interactions with various residues. Alfentanil (N), Alfentanil 
(N2), Alfentanil (ethyl), and Alfentanil (methyl1) all had one π-π stacking interaction 
with Trp 293, while Alfentanil (N3) had two π-π stacking interactions, one with Trp 293 
and the other with Tyr 326. Alfentanil (DBC), alfentanil (N2), alfentanil (N3), alfentanil 
(N4), alfentanil (methyl) all showed both a hydrogen and salt bridge interaction with Asp 
147. Only alfentanil (N) stands apart in this category, with its hydrogen interaction 
occurring with the nitrogen on the piperidine ring, while the salt bridge interaction occurs 
with the nitrogen on the penta-ring. Alfentanil (methyl2) was the only ligand in this 
category that showed no interactions with the surrounding amino acid residues. 
Binding Energy Estimations 
As expected, based on literature research, most carfentanyl ligands showed the 
highest docking scores and some of the higher MMGBA dG binding scores when 
compared to all ligands as a whole. 
 
 
  
 21 
Table 6. This table shows the MMGBA dG binding score for each ligand 
compared to their docking score. 
 
  
The dark green represents the six ligands with the most negative docking scores 
while the white represents the six ligands with the most positive docking scores. The 
ligands shown above in dark green are the six ligands with the most negative docking 
scores, while the ligands in white are the six with the most positive docking scores. The 
light green ligands are the next six ligands with the most negative docking scores, while 
the next six can be seen in light blue. As can be seen in Table 6, carfentanyl (ethyl), 
carfentanyl, carfentanyl (aldehyde), and carfentanyl (ketone) show some of the most 
negative binding estimations. Many ligands that had low docking scores, namely N-
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propyl fentanyl, alfentanil (DBO), N-ethyl fentanyl reside lower on Table 6. These initial 
results indicate that the residues and interactions within the binding pocket fit the 
expected pattern based on the literature. All but two of the original ligands (carfentanyl 
and fentanyl) showed more positive binding scores than the designed ligands. Both 
alfentanil (DBC) and alfentanil (methyl1) showed the most negative binding scores, 
while having relatively more positive docking scores than most of the ligands in this 
research.  
 
Conclusion 
 In the future, this research could be expanded in several constructive ways.  
Firstly, more in-depth study can be conducted on the specific residues that are seen 
interacting with the receptor. For example, a study could be conducted on the amino acids 
commonly seen in the ligand diagrams including Ile 322, Gly 325, Val 300, Met 203, Leu 
200, Val 143, and Ile 144. Establishing how these amino acids and their interactions with 
the receptor contribute to the body systems would help in determining how a new 
compound might affect a body’s biochemistry. Another potential branch of research 
could involve looking at the distances of the specific interactions and how those 
interactions are influencing the docking score and binding energy estimations of the 
ligands.  
 As research into investigating the binding of fentanyl and its derivatives is 
advancing, more docking software should be used and the data produced between 
different software should be compared and contrasted. In addition, new ligands of 
fentanyl should be designed and these compared to the ligands contained within this 
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research. The old ligands as well as the newly designed ligands can be docked to other 
opioid receptors, such as the κ- and σ-opioid receptors. This data could be stored within a 
database, accessible to both researchers and law enforcement officials in order that 
science and the law can remain one step ahead of any potential new drugs before they are 
found on the street.  
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Appendix 
 
 
 
Figure A-1. The ligand interaction diagram for N-methyl fentanyl. 
 
 
 
Figure A-2. The ligand interaction diagram for N-ethyl fentanyl. 
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Figure A-3. The ligand interaction diagram for N-propyl fentanyl. 
 
 
 
Figure A-4. The ligand interaction diagram for fentanyl. 
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Figure A-5. The ligand interaction diagram for remifentanil (carboxylic acid). 
 
 
 
Figure A-6. The ligand interaction diagram for remifentanil. 
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Figure A-7. Ligand interaction diagram for carfentanyl (methyl). 
 
 
Figure A-8. The ligand interaction diagram for carfentanyl (ethyl). 
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Figure A-9. The ligand interaction diagram for carfentanyl (aldehyde). 
 
 
Figure A-10. The ligand interaction diagram for carfentanyl (ketone). 
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Figure A-11. The ligand interaction diagram for carfentanyl (carboxylic acid). 
 
Figure A-12. Ligand interaction diagram for carfentanyl. 
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Figure A-13. The ligand interaction diagram for lofentanyl. 
 
 
Figure A-14. The ligand interaction diagram for alfentanil (N). 
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Figure A-15. The ligand interaction diagram for alfentanil (N2). 
 
 
 
Figure A-16. The ligand interaction diagram for alfentanil (N3). 
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Figure A-17. The ligand interaction diagram for alfentanil (N4). 
 
 
 
 
Figure A-18. The ligand interaction diagram for alfentanil (methyl1). 
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Figure A-19. The ligand interaction diagram for alfentanil (DBC). 
 
 
 
 
Figure A-20. The ligand interaction diagram for alfentanil (DBO). 
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Figure A-21. The ligand interaction diagram for alfentanil (methyl2). 
 
Figure A-22. The ligand interaction diagram for alfentanil (ethyl). 
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Figure A-23. The ligand interaction diagram for sufentanil. 
 
 
 
Figure A-24. The ligand interaction diagram for heroin. 
 
